AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Learn more →

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

M.D. ANDERSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Oxaliplatin-Based Chemotherapy and Chemoradiotherapy or Chemoradiotherapy in Esophageal or Gastroesophageal Carcinoma

Phase 2

Completed

Conditions: Esophageal Cancer
Gastroesophageal Cancer

Interventions: Drug: 5-Fluorouracil
Drug: Oxaliplatin
Radiation: Radiation Therapy
Procedure: Surgery

First Posted Date: 2007-09-06

Last Posted Date: 2015-02-09

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 126

Registration Number: NCT00525915

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Multimedia Intervention in Patients With Familial Adenomatous Polyposis (FAP)

Not Applicable

Completed

Conditions: Colorectal Cancer
Familial Adenomatous Polyposis

Interventions: Behavioral: Web-Based Multimedia Intervention
Behavioral: Questionnaire

First Posted Date: 2007-09-06

Last Posted Date: 2021-03-23

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 31

Registration Number: NCT00525655

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Molecular Epidemiology of Therapy-related Acute Myeloid Leukemia/Myelodysplastic Syndrome (AML/MDS)

Active, not recruiting

Conditions: Myelodysplastic Syndrome
Leukemia

Interventions: Behavioral: Interview

First Posted Date: 2007-09-06

Last Posted Date: 2020-01-14

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 191

Registration Number: NCT00525746

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Temozolomide Alone or With Pegylated Interferon-Alpha 2b (PGI) in Melanoma Patients

Phase 2

Completed

Conditions: Melanoma

Interventions: Drug: Temozolomide (TMZ)
Drug: Pegylated Interferon Alpha-2b (PGI)

First Posted Date: 2007-09-05

Last Posted Date: 2020-09-23

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 55

Registration Number: NCT00525031

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Dalteparin in Preventing DVT in Participants With Cancer

Not Applicable

Completed

Conditions: Bone Sarcoma
Pathologic Fracture
Femur Fracture
Lymphoma
Metastatic Neoplasm
Plasma Cell Myeloma
Soft Tissue Sarcoma

Interventions: Drug: Dalteparin

First Posted Date: 2007-09-05

Last Posted Date: 2021-01-22

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 65

Registration Number: NCT00525057

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Allogeneic Hematopoietic Stem Cell Transplantation With Bevacizumab for Advanced Solid Tumor

Phase 2

Terminated

Conditions: Breast Cancer
Ovarian Cancer

Interventions: Drug: Bevacizumab
Procedure: Allogeneic Hematopoietic Stem Cell Transplantation
Drug: Fludarabine
Drug: Melphalan
Drug: Thymoglobulin

First Posted Date: 2007-09-03

Last Posted Date: 2013-01-28

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 5

Registration Number: NCT00523809

Locations: 🇺🇸
U.T.M.D. Anderson Cancer Center, Houston, Texas, United States

Sexual Functioning in Cervical Cancer Survivors

Completed

Conditions: Cervical Cancer

Interventions: Behavioral: Questionnaire

First Posted Date: 2007-08-29

Last Posted Date: 2018-07-17

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 111

Registration Number: NCT00522223

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Cloretazine (VNP40101M) With Hematopoietic Cell Transplantation for Hematologic Malignancies

Phase 1

Completed

Conditions: Hematologic Malignancies

Interventions: Drug: Cloretazine
Drug: Fludarabine

First Posted Date: 2007-08-28

Last Posted Date: 2012-07-31

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 5

Registration Number: NCT00521859

Locations: 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States

Treatment of Myelodysplastic Syndrome (MDS) With Cytokine-Immunotherapy for Low-Risk MDS

Phase 2

Completed

Conditions: Myelodysplastic Syndrome

Interventions: Drug: Erythropoietin
Drug: Cyclosporin A
Drug: G-CSF
Drug: Prednisone

First Posted Date: 2007-08-24

Last Posted Date: 2012-08-07

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 15

Registration Number: NCT00520468

Locations: 🇺🇸
U.T.M.D. Anderson Cancer Center, Houston, Texas, United States

3-Dimensional Conformal Radiation Therapy Versus Intensity Modulated Radiation Therapy

Phase 2

Completed

Conditions: Lung Cancer

Interventions: Procedure: 3-Dimensional Conformal Radiation Therapy
Procedure: Intensity Modulated Radiation Therapy

First Posted Date: 2007-08-24

Last Posted Date: 2018-10-05

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 168

Registration Number: NCT00520702

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Home Terms & Conditions Privacy Policy